In This Issue
Leading pet food firm buys rival company
Change dogs' llves. Stock real food!
Arden Grange lightens up for sensitive seniors
100 companies sign up to exhibit at PATS Telford...and there's still over six months to go before the big event
Carnilove hunts for first-ever brand ambassador
Launching at Crufts: the smart-tech germ-busting dog bowl that combats bacteria including MRSA
Mutneys returns to Crufts for 22nd year running
Oscar and Hooch team up with Medical Detection Dogs
Poppy’s Picnic to fly the flag at national awards
Something fishy on the WOOFS stand at Crufts
ADAPTIL and FELIWAY launch Pet Anxiety Month in March
Get your own copy of Pet Trade Xtra
Roger Mugford stepping down as CEO of Company of Animals
Top-level speakers will provide topical advice at international trade event
Pet shop owner left 'heartbroken after break-in
Pests hate CSJ’s Billy No Mates!
Scruffs to display luxury bedding at Crufts in March
Vince the Vet detox remedies for cats and dogs
Pet medicine firm raises £8m in funding
The best of the previous Pet Trade Xtra
Aldi launches new range of dog accessories
Pet store to stop stocking animals amid welfare concerns
Billy + Margot set to showcase new range at Crufts
Is insect protein the future of pet food?
CONTACT US NOW
Find out how Pet Trade Xtra can help to promote your business and products.

If you have a story for Pet Trade Xtra contact neil.pope@tgcmc.co.uk for all editorial matters.



Email ben.greenwood@tgcmc.co.uk to discuss advertising and sponsorship opportunities.
Pet medicine firm raises £8m in funding

A veterinary medicine specialist based in Cambridge has raised £8m in Series A funding.

 

PetMedix is applying 30 years of antibody research and the scientific work of two of its founders, Professor Allan Bradley and Dr Jolyon Martin, to develop new pet therapeutics against a wide range of diseases.

 

The fundraising, led by founder and chief executive Dr Tom Weaver, will be used to establish operations, grow the team, continue to build the platforms, and begin drug discovery.

 

The investment was led by Digitalis Ventures (NYC) with Parkwalk Advisors (London) as its syndicate partner.

 

"Digitalis is thrilled to be a part of this journey to bring these innovative therapies to market and excited to work with the talented team that has been assembled at Petmedix," said Cindy Cole, a technical partner with Digitalis Ventures.

Facebook Twitter LinkedIn